AI Article Synopsis
- This study focused on identifying carbapenem-resistant Klebsiella pneumoniae (CRKP) strains from clinical samples and examining their antibiotic resistance genes.
- Out of 35 strains, 51.4% showed extensive drug resistance, while 31.4% showed multi-drug resistance, and 17.1% were pan-drug resistant.
- Molecular techniques revealed specific resistance genes and types for the strains, with significant findings including the first molecular analysis of CRKP strains from Siirt, Türkiye.
Article Abstract
This study aimed to molecularly identify carbapenem-resistant Klebsiella pneumoniae (CRKP) strains isolated from clinical samples and to determine antibiotic resistance genes. Only carbapenem-resistant strains were included in our study. Of the 35 CRKP strains, 18 (51.4%) were extensive drug, 11 (31.4%) were multi-drug, and 6 (17.1%) were pan-drug resistances. PCR amplification revealed that 25% of the strains carried the OXA-51, 20% the OXA-48, and %5 the OXA23 genes. Multilocus sequence typing (MLST) analysis based on seven house-keeping genes revealed sequence type 39. The capsule and O-antigen types were determined as KL103 and O2a, respectively. WGS analysis revealed the existence of β-lactamase, aminoglycoside, sulfonamide, Phenicol, and Fosfomycin-resistant genes. While the K. pneumoniae OmpK37 gene was detected in all 3 strains, the OmpK36 gene was detected only in the CRSU20 strain. This study is important as it is the first study to perform molecular analysis of CRKP strains from Siirt, Türkiye.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diagmicrobio.2024.116414 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The in vitro Activity of Omadacycline Alone and in Combination Against Carbapenem-Resistant .
Infect Drug Resist
December 2024
Intensive Care Medical Center, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, People's Republic of China.
Objective: This study aimed to evaluate the in vitro activity of omadacycline (OMC) and OMC-based combination therapy against carbapenem-resistant (CRKP).
Methods: The broth microdilution assay assessed the in vitro susceptibility of CRKP to OMC. The checkerboard assay was performed to evaluate the activity of OMC combined with polymyxin B (PB), amikacin (AN), or meropenem (MEM) against KPC-producing (class A) CRKP strains, and OMC combined with PB, aztreonam (ATM), MEM, or AN against class B and class A plus class B CRKP strains.
Epidemiology, antimicrobial resistance profile, associated risk factors and management of carbapenem resistant Klebsiella pneumoniae in children under 5 with suspected sepsis in Ethiopia.
BMC Infect Dis
December 2024
Institute of Biotechnology, Addis Ababa University P.O.Box.1176, Addis Ababa, Ethiopia.
Background: Early detection and treatment of carbapenem-resistant Klebsiella pneumoniae (CRKP) could reduce the risk of developing life-threatening sepsis in childhood. However, little is known about sepsis caused by CRKP in children under-5 in developing countries. This study aimed to determine the epidemiology, antimicrobial resistance profile, associated risk factors and management of CRKP in children under-5 with sepsis in Ethiopia.
View Article and Find Full Text PDFOverexpression of KPC contributes to ceftazidime-avibactam heteroresistance in clinical isolates of carbapenem-resistant .
Front Cell Infect Microbiol
December 2024
Key Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Yangjiang, China.
Ceftazidime-avibactam (CZA) is one of the effective antibiotics used for the treatment of carbapenem-resistant (CRKP) infections, but its resistance rate has increased recently. Previous studies have focused on the mechanisms of CZA resistance, while its heteroresistance in CRKP remains poorly understood. This study aimed to investigate the characteristics and mechanisms of CZA heteroresistance in CRKP isolates.
View Article and Find Full Text PDFCharacterization of a Novel KPC-2 Variant, KPC-228, Conferring Resistance to Ceftazidime-Avibactam in an ST11-KL64 Hypervirulent Klebsiella pneumoniae.
Int J Antimicrob Agents
December 2024
Department of Clinical Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address:
Article Synopsis
- The study investigates the mechanisms of resistance to ceftazidime-avibactam (CZA) in a hypervirulent strain of Klebsiella pneumoniae known as CRE146, which carries the bla gene.
- Researchers isolated twelve carbapenem-resistant Klebsiella pneumoniae strains from a single patient, employing whole genome sequencing and various pathogenicity tests to understand the virulence factors and resistance development.
- Findings revealed that the resistance was linked to drug exposure and involved specific genetic mutations in carbapenemase (KPC-228), with CRE146 showing high resistance to CZA while being more susceptible to other antibiotics like meropenem and imipenem.
A combined therapy of meropenem-ZnO nanoparticles efficiently eliminates carbapenem-resistant Klebsiella pneumoniae biofilms, with reduced nephrotoxicity (in vitro).
Lett Appl Microbiol
December 2024
Microbiology and Botany Department, Faculty of Science, Zagazig University,Zagazig 44519, Egypt.
In response to the World Health Organization's research agenda of antimicrobial resistance in human health, this study appraised the antibacterial and antibiofilm synergistic activity of meropenem and ZnO nanoparticles (ZnO-NPs) combination against carbapenem-resistant Klebsiella pneumoniae (CRKP). The minimum inhibitory concentration (MIC) of meropenem in combination was found to be ~1/12 of its MIC alone. The results of microtiter dilution assay showed that the combination was more efficient in reducing the biofilm biomass than meropenem alone or ZnO-NPs alone.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!